Eli Lilly reported that retatrutide met primary and all key secondary endpoints in a phase III trial for type 2 diabetes, delivering significant reductions in HbA1c and substantial weight loss. The company disclosed Transcend‑T2D‑1 top-line data showing up to a 1.9 percentage‑point A1C drop and mean weight loss of up to 36.6 pounds at 40 weeks on the highest dose. The trial enrolled adults with T2D inadequately controlled by diet and exercise; Lilly presented aggregated efficacy and safety results, noting a side‑effect profile consistent with GLP‑class agents (nausea, diarrhea, vomiting). Independent endocrinologists cited preliminary comparisons to existing dual‑agonists and praised the magnitude of combined glycemic and weight effects, while flagging the need for peer‑reviewed data on long‑term safety. Lilly’s release also included investor‑facing summaries positioning retatrutide as a next‑generation metabolic candidate with potential to address both glycemic control and obesity. Regulators will require full datasets for labeling and risk evaluation; companies and payers are watching for durability, safety signals, and how the therapy will be deployed clinically.